SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001819790-21-000053
Filing Date
2021-11-10
Accepted
2021-11-10 16:13:46
Documents
58
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tars-20210930.htm   iXBRL 10-Q 1178244
2 EX-31.1 exhibit31193021.htm EX-31.1 11881
3 EX-31.2 exhibit31293021.htm EX-31.2 12137
4 EX-32.1 exhibit32193021.htm EX-32.1 9973
5 EX-32.2 exhibit32293021.htm EX-32.2 9915
  Complete submission text file 0001819790-21-000053.txt   5346097

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20210930.xsd EX-101.SCH 34006
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT tars-20210930_cal.xml EX-101.CAL 64127
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT tars-20210930_def.xml EX-101.DEF 149849
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20210930_lab.xml EX-101.LAB 450470
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20210930_pre.xml EX-101.PRE 286202
11 EXTRACTED XBRL INSTANCE DOCUMENT tars-20210930_htm.xml XML 864182
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39614 | Film No.: 211396740
SIC: 2836 Biological Products, (No Diagnostic Substances)